Synthesis and Preliminary Antiviral Activities of Piperidine‐substituted Purines against HIV and Influenza A/H1N1 Infections
暂无分享,去创建一个
E. De Clercq | Dongwei Kang | Zengjun Fang | Boshi Huang | Lingzi Zhang | Huiqing Liu | C. Pannecouque | L. Naesens | P. Zhan | Xinyong Liu
[1] R. Gallo,et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.
[2] F. Brun-Vézinet,et al. Isolation of a new human retrovirus from West African patients with AIDS. , 1986, Science.
[3] H. Klenk,et al. Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors , 2003, Journal of Virology.
[4] C. Pannecouque,et al. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later , 2008, Nature Protocols.
[5] J. Jekő,,et al. Anti-influenza virus activity and structure–activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains , 2009, Antiviral Research.
[6] Peng Zhan,et al. Design strategies of novel NNRTIs to overcome drug resistance. , 2009, Current medicinal chemistry.
[7] Peng Zhan,et al. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. , 2009, Current medicinal chemistry.
[8] Xiaohong Liu,et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.
[9] L. Naesens,et al. Novel Inhibitors of Influenza Virus Fusion: Structure-Activity Relationship and Interaction with the Viral Hemagglutinin , 2010, Journal of Virology.
[10] Hong Lu,et al. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.
[11] Xianfeng Lin,et al. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.
[12] Hong Lu,et al. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.
[13] E. De Clercq,et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. , 2011, Current medicinal chemistry.
[14] Peng Zhan,et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 – 2010) , 2011, Expert opinion on therapeutic patents.
[15] Peng Zhan,et al. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. , 2012, Bioorganic & medicinal chemistry.
[16] Peng Zhan,et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. , 2012, Journal of medicinal chemistry.
[17] M. Wainberg,et al. Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors , 2012, Antimicrobial Agents and Chemotherapy.
[18] E. De Clercq,et al. Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents , 2012, Archives of Pharmacal Research.
[19] Bingjie Qin,et al. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. , 2012, Journal of medicinal chemistry.
[20] Peng Zhan,et al. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. , 2013, Bioorganic & medicinal chemistry.
[21] Huiqing Liu,et al. Discovery of Piperidine‐Linked Pyridine Analogues as Potent Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors , 2013, ChemMedChem.
[22] P. Zhan,et al. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. , 2013, Current pharmaceutical design.
[23] Peng Zhan,et al. HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design , 2013, Medicinal research reviews.
[24] Peng Zhan,et al. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. , 2014, Bioorganic & medicinal chemistry.
[25] Peng Zhan,et al. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. , 2014, European journal of medicinal chemistry.
[26] Peng Zhan,et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011 – 2014) , 2014, Expert opinion on therapeutic patents.
[27] E. De Clercq,et al. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. , 2014, European journal of medicinal chemistry.
[28] Peng Zhan,et al. Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. , 2014, European journal of medicinal chemistry.
[29] Peng Zhan,et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. , 2014, Bioorganic & medicinal chemistry.
[30] Peng Zhan,et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. , 2014, European journal of medicinal chemistry.
[31] Peng Zhan,et al. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. , 2014, Molecular bioSystems.
[32] Peng Zhan,et al. "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. , 2014, Combinatorial chemistry & high throughput screening.
[33] Peng Zhan,et al. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. , 2013, Current medicinal chemistry.
[34] E. De Clercq,et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. , 2015, European journal of medicinal chemistry.